Tony Berberabe, MPH

Articles

Genomic Classifier Refines Risk Calculation After Prostatectomy

February 1st 2016

Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.

Ublituximab Is Combined With Ibrutinib in High-Risk CLL Study

January 13th 2016

Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.

Expert Predicts PD-1/PD-L1 Agents as Backbone of Combination Therapy in RCC

January 6th 2016

PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).

Prevalence of DNA Repair Defects Key to Efficacy of PARP Inhibitors in Prostate Cancer

January 6th 2016

Clinical studies suggest that PARP inhibitors are highly efficacious in patients with metastatic castration-resistant prostate cancer with these alternations in DNA repair genes.

Liquid Biopsy Paves Way for Personalized Selection Tool in Prostate Cancer

January 4th 2016

The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.

Prostate Cancer Guidelines Lack Molecular Test Recommendations

December 15th 2015

When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristicâ€”the lack of a molecular test in tissue-based platforms at this point in time.

Men With High-Risk Prostate Cancer Undergoing More Prostatectomies

December 2nd 2015

Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.

Personalized Peptide Vaccination Increased Survival in Advanced Bladder Cancer

November 28th 2015

The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.

Swedish Biomarker Test STHLM3 Identifies Aggressive Form of Prostate Cancer

November 26th 2015

A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.

Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

November 21st 2015

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal

November 7th 2015

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

Novel Combinations Hold Promise in Treatment-Resistant mCRPC

November 6th 2015

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

LUGPA Meeting Focuses on Business and Clinical Challenges

November 4th 2015

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

Enhanced Immune Response Seen With Radiation/Ipilimumab Combo in Melanoma

October 24th 2015

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic antiâ€“CTLA-4 immunotherapy, ipilimumab.

High-Intensity Ultrasound Device for Prostate Surgery Clears FDA Hurdle

October 13th 2015

The FDA has issued a de novo clearance for a minimally invasive high-intensity focused ultrasound for prostate tissue ablation called Sonablate 450 and marketed by SonaCare Medical, LLC.

In Kidney Cancer, Better Outcomes Demonstrated With Nephron-sparing Surgery

October 12th 2015

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

One Clinic's Multidisciplinary Approach Optimizes the Use of Radium-223

September 20th 2015

With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.

Start Discussions About Palliative Care Upon Initial Metastatic Diagnosis

August 11th 2015

In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.

Early Docetaxel, ADT Combo Increases Survival in Advanced Prostate Cancer

August 10th 2015

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

New Diagnoses of Prostate Cancer Decline Nearly 30% Following USPSTF PSA Decision

August 6th 2015

New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.